$1.42
-2.1%OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Chief Business Officer
Chief Financial Officer
Compensation
$36,000
Chief Medical Officer & Chief Scientific Officer
Compensation
$420,000
Chief of Staff
Founder, Chairman, President & Chief Executive Officer
Compensation
$680,000
During the last 12 months, there has been no insider trading activity reported for OSTX.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
No buying activity
No selling activity
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
No insider trading activity reported from any insiders in the past year.
OSTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | August 25, 2025 | October 14, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | February 28, 2025 | March 31, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.